Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

M. C. Robson; L. G. Phillips; A. Thomason; B. W. Altrock; P. C. Pence; J. P. Heggers; A. F. Johnston; T. P. McHugh; M. S. Anthony; L. E. Robson; L. L. Odom; D. Yanagihara; G. F. Pierce

doi:10.1097/00000637-199209000-00001

Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

M. C. Robson
, L. G. Phillips
, A. Thomason
, B. W. Altrock
, P. C. Pence
, J. P. Heggers
, A. F. Johnston
, T. P. McHugh
, M. S. Anthony
, L. E. Robson
, L. L. Odom
, D. Yanagihara
, G. F. Pierce

Surgery

Research output: Contribution to journal › Article › peer-review

117 Scopus citations

Abstract

A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm²) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

Original language	English (US)
Pages (from-to)	193-201
Number of pages	9
Journal	Annals of plastic surgery
Volume	29
Issue number	3
DOIs	https://doi.org/10.1097/00000637-199209000-00001
State	Published - 1992

ASJC Scopus subject areas

Surgery

Access to Document

10.1097/00000637-199209000-00001

Cite this

Robson, M. C., Phillips, L. G., Thomason, A., Altrock, B. W., Pence, P. C., Heggers, J. P., Johnston, A. F., McHugh, T. P., Anthony, M. S., Robson, L. E., Odom, L. L., Yanagihara, D., & Pierce, G. F. (1992). Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Annals of plastic surgery, 29(3), 193-201. https://doi.org/10.1097/00000637-199209000-00001

Robson, MC, Phillips, LG, Thomason, A, Altrock, BW, Pence, PC, Heggers, JP, Johnston, AF, McHugh, TP, Anthony, MS, Robson, LE, Odom, LL, Yanagihara, D & Pierce, GF 1992, 'Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers', Annals of plastic surgery, vol. 29, no. 3, pp. 193-201. https://doi.org/10.1097/00000637-199209000-00001

@article{65efd1f5c9fe4bb1bab74f492dffb93d,

title = "Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers",

abstract = "A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.",

author = "Robson, \{M. C.\} and Phillips, \{L. G.\} and A. Thomason and Altrock, \{B. W.\} and Pence, \{P. C.\} and Heggers, \{J. P.\} and Johnston, \{A. F.\} and McHugh, \{T. P.\} and Anthony, \{M. S.\} and Robson, \{L. E.\} and Odom, \{L. L.\} and D. Yanagihara and Pierce, \{G. F.\}",

year = "1992",

doi = "10.1097/00000637-199209000-00001",

language = "English (US)",

volume = "29",

pages = "193--201",

journal = "Annals of plastic surgery",

issn = "0148-7043",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

AU - Robson, M. C.

AU - Phillips, L. G.

AU - Thomason, A.

AU - Altrock, B. W.

AU - Pence, P. C.

AU - Heggers, J. P.

AU - Johnston, A. F.

AU - McHugh, T. P.

AU - Anthony, M. S.

AU - Robson, L. E.

AU - Odom, L. L.

AU - Yanagihara, D.

AU - Pierce, G. F.

PY - 1992

Y1 - 1992

N2 - A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

AB - A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

UR - https://www.scopus.com/pages/publications/0026737331

UR - https://www.scopus.com/pages/publications/0026737331#tab=citedBy

U2 - 10.1097/00000637-199209000-00001

DO - 10.1097/00000637-199209000-00001

M3 - Article

C2 - 1524367

AN - SCOPUS:0026737331

SN - 0148-7043

VL - 29

SP - 193

EP - 201

JO - Annals of plastic surgery

JF - Annals of plastic surgery

IS - 3

ER -

Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this